1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. Europe Prostate Cancer Nuclear Medicine Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. Europe Prostate Cancer Nuclear Medicine Market – Key Market Dynamics
5.4 Impact of Drivers and Restraints
6. Europe Prostate Cancer Nuclear Medicine Market Regional Analysis
6.1 Europe Prostate Cancer Nuclear Medicine Market Overview
6.2 Europe Prostate Cancer Nuclear Medicine Market Revenue 2020-2028 (US$ Million)
6.3 Europe Prostate Cancer Nuclear Medicine Market Forecast Analysis
7. Europe Prostate Cancer Nuclear Medicine Market Analysis – by Type
7.1 PET
- 7.1.1 Overview
- 7.1.2 PET: Europe Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2031 (US$ Million)
7.2 SPECT
- 7.2.1 Overview
- 7.2.2 SPECT: Europe Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2031 (US$ Million)
8. Europe Prostate Cancer Nuclear Medicine Market Analysis – by PET Product
8.1 F-18
- 8.1.1 Overview
- 8.1.2 F-18: Europe Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2028 (US$ Million)
8.2 C-11
- 8.2.1 Overview
- 8.2.2 C-11: Europe Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2028 (US$ Million)
8.3 Ga68-PSMA
- 8.3.1 Overview
- 8.3.2 Ga68-PSMA: Europe Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2028 (US$ Million)
9. Europe Prostate Cancer Nuclear Medicine Market Analysis – by End User
9.1 Hospitals
- 9.1.1 Overview
- 9.1.2 Ga68-PSMA: Europe Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2028 (US$ Million)
9.2 Clinics
- 9.2.1 Overview
- 9.2.2 Ga68-PSMA: Europe Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2028 (US$ Million)
10. Europe Prostate Cancer Nuclear Medicine Market – Europe Analysis
10.1 Europe
- 10.1.1 Europe Prostate Cancer Nuclear Medicine Market Breakdown, by Key
Country, 2023 and 2028 (%)
- 10.1.1.1 Europe Prostate Cancer Nuclear Medicine Market – Revenue and
Forecast Analysis – by Country
- 10.1.1.1 UK:
Europe Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.1.1 UK: Europe Prostate Cancer Nuclear Medicine Market Breakdown, by Type
- 10.1.1.1.2 UK: Europe Prostate Cancer Nuclear Medicine Market Breakdown, by PET Product
- 10.1.1.1.3 UK: Europe Prostate Cancer Nuclear Medicine Market Breakdown, by End User
- 10.1.1.2 Germany:
Europe Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.2.1 Germany: Europe Prostate Cancer Nuclear Medicine Market Breakdown, by Type
- 10.1.1.2.2 Germany: Europe Prostate Cancer Nuclear Medicine Market Breakdown, by PET Product
- 10.1.1.2.3 Germany: Europe Prostate Cancer Nuclear Medicine Market Breakdown, by End User
- 10.1.1.3 France:
Europe Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.3.1 France: Europe Prostate Cancer Nuclear Medicine Market Breakdown, by Type
- 10.1.1.3.2 France: Europe Prostate Cancer Nuclear Medicine Market Breakdown, by PET Product
- 10.1.1.3.3 France: Europe Prostate Cancer Nuclear Medicine Market Breakdown, by End User
- 10.1.1.4 Russia:
Europe Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.4.1 Russia: Europe Prostate Cancer Nuclear Medicine Market Breakdown, by Type
- 10.1.1.4.2 Russia: Europe Prostate Cancer Nuclear Medicine Market Breakdown, by PET Product
- 10.1.1.4.3 Russia: Europe Prostate Cancer Nuclear Medicine Market Breakdown, by End User
- 10.1.1.5 Italy:
Europe Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.5.1 Italy: Europe Prostate Cancer Nuclear Medicine Market Breakdown, by Type
- 10.1.1.5.2 Italy: Europe Prostate Cancer Nuclear Medicine Market Breakdown, by PET Product
- 10.1.1.5.3 Italy: Europe Prostate Cancer Nuclear Medicine Market Breakdown, by End User
- 10.1.1.6 Rest of Europe:
Europe Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.6.1 Rest of Europe: Europe Prostate Cancer Nuclear Medicine Market Breakdown, by Type
- 10.1.1.6.2 Rest of Europe: Europe Prostate Cancer Nuclear Medicine Market Breakdown, by PET Product
- 10.1.1.6.3 Rest of Europe: Europe Prostate Cancer Nuclear Medicine Market Breakdown, by End User
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Europe Prostate Cancer Nuclear Medicine Market Industry Landscape
12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments
13. Company Profiles
13.1 Blue Earth Diagnostics Limited
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 ImaginAb
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Curium
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Jubilant Radiopharma
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 ABX advanced biochemical compounds GmbH
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Telix Pharmaceuticals Ltd
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Novartis AG
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Theragnostics
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Lantheus Medical Imaging, Inc.
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
14. Appendix
14.1 About Business Market Insights